REYNOLDS, MARK,雷纳德 马克,雷納德 馬克,EARY, CHARLES TODD,厄立 查李斯 陶德
申请号：
TW107135654
公开号：
TW201922252A
申请日:
2018.10.09
申请国别(地区):
TW
年份:
2019
代理人:
摘要：
6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl) methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders,e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.本發明揭示6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈或其醫藥學上可接受之鹽、非晶形式、多形體形式或醫藥組合物(包括固體調配物或液體調配物)，及其用於治療能用RET激酶抑制劑治療之疾病及病症的用途，諸如RET相關疾病及病症，例如增殖病症，諸如癌症，包括血液癌症及實體腫瘤，以及胃腸病症，諸如IBS。
